ArticleBMC bioinformatics2025
Research on drug-drug interaction prediction using capsule neural network based on self-attention mechanism.
Article in BMC bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early prediction and risk assessment of adverse drug combinations using ensemble learning.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMulti-drug combinations represent an effective strategy for treating complex diseases. However, due to the vast number of unknown interactions among drugs, accurately predicting drug-drug interactions (DDIs) is essential for preventing adverse drug reactions that may cause serious harm to patients. Therefore, DDI prediction plays a critical role in pharmacology.
resultsIn this paper, we propose a novel DDI prediction model that integrates a self-attention mechanism with a capsule neural network, termed ACaps-DDI. The model effectively combines chemical information from internal drug substructures with biological information from external drug targets and drug-metabolizing enzymes to predict potential drug-drug interactions.
conclusionsExperimental results on two benchmark datasets show that the ACaps-DDI model outperforms six other classification models across seven evaluation metrics, demonstrating its strong predictive performance and generalization ability. Ablation studies further confirm the effectiveness of individual components within the ACaps-DDI architecture. Finally, case studies involving three drugs (cannabidiol, torasemide, and cyclophosphamide) validate the model's ability to predict previously unknown drug interactions. In conclusion, the ACaps-DDI model exhibits high predictive accuracy for known drugs and demonstrates promising predictive capability for unseen drugs, highlighting its practical significance for clinical research on drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.